Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 5/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.34 |
| ▸ | CIT | O14578 | 2/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.34 |
| ▸ | STK10 | O94804 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.34 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.34 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 0.34 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15191841 | 0.94 | BRAF (0.37) | MEN1KMT2ABRAFCSNK1DCSNK1E | |
| SCHEMBL574846 | 0.93 | BRAF (0.33) | BRAFCSNK1DCSNK1EMAPK3MAPK1 | |
| SCHEMBL15192209 | 0.91 | PDE10A (0.36) | CSNK1DCSNK1EPTGS2MAPK13MAPK12 | |
| SCHEMBL10220624 | 0.90 | PIK3CA (0.34) | BRAFCSNK1DRIPK2STK10MAP4K4 | |
| SCHEMBL15191686 | 0.89 | ROS1 (0.33) | — | |
| SCHEMBL575000 | 0.87 | BRAF (0.34) | BRAFCSNK1DCSNK1ERIPK2MAPK13 | |
| SCHEMBL2316779 | 0.85 | MAPK14 (0.34) | BRAFCSNK1DCSNK1EMAPK3MAPK1 | |
| SCHEMBL574504 | 0.85 | EGFR (0.37) | BRAFCSNK1DCSNK1ERIPK2TGFBR1 | |
| SCHEMBL575015 | 0.84 | MET (0.33) | BRAFMAPK3MAPK1 | |
| SCHEMBL15191983 | 0.83 | EGFR (0.38) | BRAFMAPK3MAPK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| EP-2601185-B1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-10-07 | — | — | EP | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-9114137-B2 | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-25 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-08-22 | — | — | US | disclosed |
| EP-2601185-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016993-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217715-A1 | DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS | CDK2, CDK1, CDK4 | MEN1 1876/4885KMT2A 1643/4885BRAF 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.